Tamoxifen may contribute to preserve cardiac function in Duchenne muscular dystrophy.
Cardiomyopathy
Dilated cardiomyopathy
Duchenne muscular dystrophy
Heart failure
Tamoxifen
Journal
European journal of pediatrics
ISSN: 1432-1076
Titre abrégé: Eur J Pediatr
Pays: Germany
ID NLM: 7603873
Informations de publication
Date de publication:
03 Jul 2024
03 Jul 2024
Historique:
received:
31
01
2024
accepted:
24
06
2024
revised:
20
05
2024
medline:
4
7
2024
pubmed:
4
7
2024
entrez:
3
7
2024
Statut:
aheadofprint
Résumé
Duchenne muscular dystrophy is life-limiting. Cardiomyopathy, which mostly ensues in the second decade of life, is the main cause of death. Treatment options are still limited. The TAMDMD (NCT03354039) trial assessed motor function, muscle strength and structure, laboratory biomarkers, and safety in 79 ambulant boys with genetically confirmed Duchenne muscular dystrophy, 6.5-12 years of age, receiving either daily tamoxifen 20 mg or placebo for 48 weeks. In this post-hoc analysis, available echocardiographic data of ambulant patients recruited at one study centre were retrieved and compared before and after treatment. Data from 14 patients, median 11 (interquartile range, IQR, 11-12) years of age was available. Baseline demographic characteristics were similar in participants assigned to placebo (n = 7) or tamoxifen (n = 7). Left ventricular end-diastolic diameter in the placebo group (median and IQR) was 39 (38-41) mm at baseline and 43 (38-44) mm at study end, while it was 44 (41-46) mm at baseline and 41 (37-46) mm after treatment in the tamoxifen group. Left ventricular fractional shortening in the placebo group was 35% (32-38%) before and 33% (32-36%) after treatment, while in the tamoxifen group it was 34% (33-34%) at baseline and 35% (33-35%) at study end. No safety signals were detected. This hypothesis-generating post-hoc analysis suggests that tamoxifen over 48 weeks is well tolerated and may help preserving cardiac structure and function in Duchenne muscular dystrophy. Further studies are justified. gov Identifier: EudraCT 2017-004554-42, NCT03354039 What is known: • Duchenne muscular dystrophy (DMD) is life-limiting. Cardiomyopathy ensues in the second decade of life and is the main cause of death. Treatment options are still limited. • Tamoxifen reduced cardiac fibrosis in mice and improved cardiomyocyte function in human-induced pluripotent stem cell-derived cardiomyocytes. • In this post-hoc analysis of the TAMDMD trial among 14 boys, median 11 years of age, treated with either tamoxifen or placebo for 48 weeks, treatment was well-tolerated. • A visual trend of improved left-ventricular dimensions and better systolic function preservation generates the hypothesis of a potential beneficial effect of tamoxifen in DMD cardiomyopathy.
Identifiants
pubmed: 38960907
doi: 10.1007/s00431-024-05670-9
pii: 10.1007/s00431-024-05670-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Birnkrant DJ, Bushby K, Bann CM, Alman BA, Apkon SD, Blackwell A et al (2018) Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol 17(4):347–361
doi: 10.1016/S1474-4422(18)30025-5
pubmed: 29395990
pmcid: 5889091
Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D et al (2018) Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol 17(3):251–267
doi: 10.1016/S1474-4422(18)30024-3
pubmed: 29395989
pmcid: 5869704
Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Colvin MK et al (2018) Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan. Lancet Neurol 17(5):445–455
doi: 10.1016/S1474-4422(18)30026-7
pubmed: 29398641
pmcid: 5902408
Emery AE (2002) Muscular dystrophy into the new millennium. Neuromuscular disorders NMD 12(4):343–349
doi: 10.1016/S0960-8966(01)00303-0
pubmed: 12062251
Bourke JP, Bueser T, Quinlivan R (2018) Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy. Cochrane Database Syst Rev 10(10):Cd009068
pubmed: 30326162
Eagle M, Baudouin SV, Chandler C, Giddings DR, Bullock R, Bushby K (2002) Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord 12(10):926–929
doi: 10.1016/S0960-8966(02)00140-2
pubmed: 12467747
Muntoni F (2003) Cardiomyopathy in muscular dystrophies. Curr Opin Neurol 16(5):577–583
doi: 10.1097/00019052-200310000-00003
pubmed: 14501841
Adorisio R, Mencarelli E, Cantarutti N, Calvieri C, Amato L, Cicenia M et al (2020) Duchenne dilated cardiomyopathy: cardiac management from prevention to advanced cardiovascular therapies. J Clin Med 9(10):3186
doi: 10.3390/jcm9103186
pubmed: 33019553
pmcid: 7600130
Cheeran D, Khan S, Khera R, Bhatt A, Garg S, Grodin JL et al (2017) Predictors of death in adults with Duchenne muscular dystrophy-associated cardiomyopathy. J Am Heart Assoc 6(10):e006340
doi: 10.1161/JAHA.117.006340
pubmed: 29042427
pmcid: 5721845
Dorchies OM, Reutenauer-Patte J, Dahmane E, Ismail HM, Petermann O, Patthey- Vuadens O et al (2013) The anticancer drug tamoxifen counteracts the pathology in a mouse model of Duchenne muscular dystrophy. Am J Pathol 182(2):485–504
doi: 10.1016/j.ajpath.2012.10.018
pubmed: 23332367
Lawrence SE, Faught KA, Vethamuthu J, Lawson ML (2004) Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia. J Pediatr 145(1):71–76
doi: 10.1016/j.jpeds.2004.03.057
pubmed: 15238910
Nagy S, Hafner P, Schmidt S, Rubino-Nacht D, Schädelin S, Bieri O et al (2019) Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trial. Trials 20(1):637
doi: 10.1186/s13063-019-3740-6
pubmed: 31752977
pmcid: 6869203
Henzi BC, Schmidt S, Nagy S, Rubino-Nacht D, Schaedelin S, Putananickal N et al (2023) Safety and efficacy of tamoxifen in boys with Duchenne muscular dystrophy (TAMDMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 22(10):890–899
doi: 10.1016/S1474-4422(23)00285-5
pubmed: 37739572
Abdelsayed M, Kort EJ, Jovinge S, Mercola M (2022) Repurposing drugs to treat cardiovascular disease in the era of precision medicine. Nat Rev Cardiol 19(11):751–764
doi: 10.1038/s41569-022-00717-6
pubmed: 35606425
pmcid: 9125554
Lopez L, Colan SD, Frommelt PC, Ensing GJ, Kendall K, Younoszai AK et al (2010) Recommendations for quantification methods during the performance of a pediatric echocardiogram: a report from the Pediatric Measurements Writing Group of the American Society of Echocardiography Pediatric and Congenital Heart Disease Council. J Am Soc Echocardiogr. 23(5):465–95 (quiz 576-7)
doi: 10.1016/j.echo.2010.03.019
pubmed: 20451803
Rossano JW, Kim JJ, Decker JA, Price JF, Zafar F, Graves DE et al (2012) Prevalence, morbidity, and mortality of heart failure-related hospitalizations in children in the United States: a population-based study. J Card Fail 18(6):459–470
doi: 10.1016/j.cardfail.2012.03.001
pubmed: 22633303
Ahmed H, VanderPluym C (2021) Medical management of pediatric heart failure. Cardiovasc Diagn Ther 11(1):323–335
doi: 10.21037/cdt-20-358
pubmed: 33708503
pmcid: 7944205
Andrews RE, Fenton MJ, Dominguez T, Burch M (2016) Heart failure from heart muscle disease in childhood: a 5–10 year follow-up study in the UK and Ireland. ESC Heart Fail 3(2):107–114
doi: 10.1002/ehf2.12082
pubmed: 27812385
pmcid: 5066798
Lava SAG, Zollinger C, Chehade H, Schaffner D, Sekarski N, Di Bernardo S (2023) Diuretics in pediatrics. Eur J Pediatr 182(5):2077–2088
doi: 10.1007/s00431-022-04768-2
pubmed: 36595088
Sperotto F, López Guillén JL, Milani GP, Lava SAG (2023) Advances in pediatric cardiology. Eur J Pediatr 183(3):983–985
doi: 10.1007/s00431-023-05196-6
Spurney CF, McCaffrey FM, Cnaan A, Morgenroth LP, Ghelani SJ, Gordish-Dressman H et al (2015) Feasibility and reproducibility of echocardiographic measures in children with muscular dystrophies. J Am Soc Echocardiogr 28(8):999–1008
doi: 10.1016/j.echo.2015.03.003
pubmed: 25906753
pmcid: 4526320
Bourke J, Turner C, Bradlow W, Chikermane A, Coats C, Fenton M et al (2022) Cardiac care of children with dystrophinopathy and females carrying DMD-gene variations. Open Heart 9(2):e001977
Verhaert D, Richards K, Rafael-Fortney JA, Raman SV (2011) Cardiac involvement in patients with muscular dystrophies: magnetic resonance imaging phenotype and genotypic considerations. Circ Cardiovasc Imaging 4(1):67–76
doi: 10.1161/CIRCIMAGING.110.960740
pubmed: 21245364
pmcid: 3057042
Clout AE, Della Pasqua O, Hanna MG, Orlu M, Pitceathly RDS (2019) Drug repurposing in neurological diseases: an integrated approach to reduce trial and error. J Neurol Neurosurg Psychiatry 90(11):1270–1275
doi: 10.1136/jnnp-2019-320879
pubmed: 31171583
Schranz D, Voelkel NF (2016) “Nihilism” of chronic heart failure therapy in children and why effective therapy is withheld. Eur J Pediatr 175(4):445–455
doi: 10.1007/s00431-016-2700-3
pubmed: 26895877
pmcid: 4806719
Birnbaum F, Eguchi A, Pardon G, Chang ACY, Blau HM (2022) Tamoxifen treatment ameliorates contractile dysfunction of Duchenne muscular dystrophy stem cell-derived cardiomyocytes on bioengineered substrates. NPJ Regen Med 7(1):19
doi: 10.1038/s41536-022-00214-x
pubmed: 35304486
pmcid: 8933505
Sheiner LB (1997) Learning versus confirming in clinical drug development. Clin Pharmacol Ther 61(3):275–291
doi: 10.1016/S0009-9236(97)90160-0
pubmed: 9084453